Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment.

ABSTRACT:

Backgrounds

Remdesivir (RDV) is an antiviral agent approved for the treatment of coronavirus disease 2019 (COVID-19); however, is not recommended for patients with renal impairment. Due to limitations associated with prospective clinical trials, real-world data on the safety and efficacy of RDV in patients with renal impairment are necessary.

Methods

Propensity score-matched (PSM) retrospective analysis was conducted between March 2020 and September 2022 in COVID-19 patients with an eGFR < 30 mL/min in four Korean hospitals. The RDV treatment group was matched to the untreated control group. The safety and clinical outcomes in patients who received RDV were analyzed.

Results

A total of 564 patients were enrolled; 229 patients received RDV either for treatment or proph

SUBMITTER: Yang E 

PROVIDER: S-EPMC10759744 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature